These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 30378120

  • 1. von Willebrand factor clearance - biological mechanisms and clinical significance.
    O'Sullivan JM, Ward S, Lavin M, O'Donnell JS.
    Br J Haematol; 2018 Oct; 183(2):185-195. PubMed ID: 30378120
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
    Favaloro EJ, Thom J, Patterson D, Just S, Dixon T, Koutts J, Baccala M, Rowell J, Baker R.
    Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
    [Abstract] [Full Text] [Related]

  • 4. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance.
    Castaman G, Tosetto A, Federici AB, Rodeghiero F.
    Thromb Haemost; 2011 Apr; 105(4):647-54. PubMed ID: 21264446
    [Abstract] [Full Text] [Related]

  • 5. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A, Berneman Z, Schroyens W, Michiels JJ.
    Acta Haematol; 2009 Apr; 121(2-3):128-38. PubMed ID: 19506359
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. R1205H (Vicenza) causes conformational changes in the von Willebrand factor D'D3 domains and enhances von Willebrand factor binding to clearance receptors LRP1 and SR-AI.
    Atiq F, Rawley O, O'Sullivan JM, Özbil M, Doherty D, Cooke N, Terraube V, Chion A, Amin A, Hulshof AM, Baci B, Byrne C, Aburawi HE, Lillicrap D, O'Donnell JS.
    J Thromb Haemost; 2024 Oct; 22(10):2752-2760. PubMed ID: 38996914
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A, van der Planken M, Schroyens W, Berneman Z, Michiels JJ.
    Acta Haematol; 2009 Oct; 121(2-3):145-53. PubMed ID: 19506361
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J, López-Fernández MF, Fraga EL, Trillo AR, Pérez-Rodríguez MA.
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [Abstract] [Full Text] [Related]

  • 17. Response to DDAVP in children with von Willebrand disease type 2.
    Schneppenheim R, Budde U, Beutel K, Hassenpflug WA, Hauch H, Obser T, Oyen F, Schneppenheim S, Schrum J.
    Hamostaseologie; 2009 May; 29(2):143-8. PubMed ID: 19404524
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.